DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Vitamin B 12
(Cont.):
folic acid and, 1087–1088
metabolic functions of, 1089
therapeutic uses of, 1090–1092
Vitamin D
absorption of, 1280–1281
adverse effects of, 1294
bone mineral mobilization and, 1283
calcium and, 1280–1283
chemistry and occurrence of, 1280
clinical uses of, 1291–1292
deficiency of, 1289
disorders, 1288–1290
excretion of, 1280–1281
history of, 1280
hydroxylation of, 1281–1282
metabolic activation of, 1281
for osteoporosis, 1300
physiological functions of,
1282–1283
requirements for, 1280
and statin-associated myalgias, 897
therapeutic indications for,
1293–1294
therapeutic uses of, 1291–1294
Vitamin D receptor, 140t
Vitamin D receptor polymorphism, 161t
Vitamin K
absorption, 873
inadequate, 874
as antidote, 86t
biliary obstruction/fistula and, 874
chemistry, 872
deficiency, symptoms, 873
excretion, 873
history, 872
human requirements for, 873
inadequate intake of, 873
inadequate utilization of, 874
occurrence, 872
pharmacokinetics of, 873
pharmacological actions of, 872–873
physiological role of, 872
therapeutic uses of, 873–874
toxicity of, 873
Vitamin K antagonist(s), 860
clinical use and monitoring of, 865
structures of, 860f
Vitamin K cycle, 861f
Vitamin K epoxide reductase, 861
Vitamin K oxioreductase (VKORC1),
160t
Vitiligo
photochemotherapy for, 1813–1814,
1814t
tacrolimus for, 1822
VITRASERT (ganciclovir), 1596t
VITRAVENE (formivirsen), 1596t
Vitreous, 1774, 1776f, 1778
VIVELLE-DOT (estradiol), 1839t
VIVELLE (estradiol), 1839t
VKORC1. See Vitamin K
oxioreductase (VKORC1)
VKORC1, genotype/haplotype
effects on warfarin, 862–863, 863t,
864
frequencies in different populations,
863t
VMA. See Vanillylmandelic acid
(VMA)
Voltage-gated channels, 59
VOLTAREN (diclofenac), 986–987
VOLTAREN-XR (diclofenac), 986–987
VOLTAROL (diclofenac), 987
Volume of distribution, 30–32
alteration for individual patients,
1807
of common drugs, 1809t–1890t
disposition and, 28
as pharmacodynamic parameter,
1804
Voriconazole, 1580–1581
arrhythmias caused by, 832
pharmacokinetics of, 1899t
polymorphisms and response to,
159t
Vorinostat, 1723–1724
VPA-977, 717
vSGLT. See Sodium galactose
transporter (vSGLT)
VYTORIN (ezetimibe and simvastatin),
904
W
Warfarin, 857
clinical use and monitoring of, 865
decreased effect of, causes, 863–864
dosage, 862
dose requirements, genetic factors
affecting, 862–863, 863t
history of, 860
mechanism of action of, 861f
metabolism of, 128t
monitoring, 862
pharmacokinetics of, 1899t
polymorphisms and, 157–158,
162f
polymorphisms and response to,
159t, 160t
and statins, interactions, 896
structure of, 860f
therapeutic uses of, 855
Warfarin-like anticoagulants,
manifestation of overdose
symptoms, 75t
Warts
bleomycin for, 1823
genital, imiquimod for, 1823
imiquimod for, 1823
Water, gastrointestinal flux of,
1328–1330
Water homeostasis, 701
WBI. See Whole bowel irrigation
(WBI)
Wegener’s granulomatosis,
cyclophosphamide
for, 1821
Weight, diuretics and, 677f
Weight reduction, sympathomimetic
amines for, 303
WELCHOL (colesevelam
hydrocholoride), 899
WELLFERON (interferon), 1596t
WESTCORT (hydrocortisone valerate),
1225t
WHI. See Women’s Health Initiative
WHITFIELD’S OINTMENT (antifungal
combination), 1817
Whole bowel irrigation (WBI),
84–85
Wilms’ tumor, drugs for, 1668t–1670t
Withdrawal syndrome, drug
abuse/addiction and,
653–654
Wolff-Parkinson-White syndrome,
management of, 824t
Wolff-Parkinson-White (WPW)
syndrome, 822, 822f
management of, 822f
Women’s Health Initiative, 1838
World War II, 239
Writing prescriptions
abbreviations in, 1880–1881
authority for, 1880
compliance and, 1881–1882
confusion in, 1880–1881
current practice, 1879–1880
date in, 1881–1882
drug product choice and amount in,
1882
errors in, 1883
history of, 1879
mechanics of, 1879–1883
patient information in, 1881
refills in, 1881–1882
signa in, 1879
subscription in, 1879
Wuchereria bancrofti, 1446
2083
INDEX